# Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia

> **NCT00019409** · PHASE3 · WITHDRAWN · sponsor: **National Institutes of Health Clinical Center (CC)**

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** asparaginase
- **DRUG:** cyclophosphamide
- **DRUG:** cytarabine
- **DRUG:** daunorubicin hydrochloride
- **DRUG:** mercaptopurine
- **DRUG:** methotrexate
- **DRUG:** prednisone
- **DRUG:** therapeutic hydrocortisone
- **DRUG:** vincristine sulfate
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00019409
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 1999-10
- **Primary completion:** —
- **Final completion:** 2001-07
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00019409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00019409, "Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00019409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*